Tubeimoside-1 Enhances TRAIL-Induced Apoptotic Cell Death through STAMBPL1-Mediated c-FLIP Downregulation

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Tubeimoside-1 (TBMS-1) is a compound from traditional Chinese medicine with known anti-cancer properties.
• Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potent inducer of apoptosis in cancer cells.
• Sensitizing cancer cells to TRAIL is a key strategy to overcome resistance in cancer therapy.

Purpose of the Study:

• To investigate the synergistic effect of TBMS-1 and TRAIL in inducing cancer cell death.
• To elucidate the molecular mechanisms underlying TBMS-1-mediated sensitization to TRAIL.
• To explore the role of STAMBPL1 and c-FLIP in this sensitization process.

Main Methods:

• In vitro studies using cancer cell lines treated with TBMS-1 and/or TRAIL at sublethal concentrations.
• Investigation of protein expression and interactions, including STAMBPL1, c-FLIP, and ubiquitination.
• In vivo xenograft mouse models to assess tumor growth inhibition and molecular changes.
• Gene knockdown experiments targeting STAMBPL1.

Main Results:

• Combination therapy of TBMS-1 and TRAIL significantly increased apoptotic cancer cell death compared to monotherapy.
• TBMS-1 was found to downregulate STAMBPL1, a deubiquitinase (DUB) essential for c-FLIP stabilization.
• STAMBPL1 knockdown enhanced cancer cell sensitivity to TRAIL by destabilizing c-FLIP.
• In vivo studies confirmed that combined TBMS-1 and TRAIL treatment reduced tumor volume and downregulated STAMBPL1 and c-FLIP.

Conclusions:

• STAMBPL1 plays a critical role in stabilizing c-FLIP.
• Depletion of STAMBPL1 enhances TRAIL-mediated apoptosis through the downregulation of c-FLIP.
• The combination of TBMS-1 and TRAIL represents a promising therapeutic strategy for sensitizing cancer cells to TRAIL-induced apoptosis.